Skip to main content
. 2015 Feb 2;9(2):1236–1249. doi: 10.1021/nn504905q

Figure 6.

Figure 6

PBAE/HSVtk nanoparticles and ganciclovir (GCV) extend survival in a 9L glioasarcoma model. Kaplan–Meier plots of F344 rats that were implanted with 9L and either given no treatment (9L Control, n = 16); 50 mg/kg twice a day of systemic administration of GCV on days 4–13 (GCV Alone, n = 8); intracranial infusion of PBAE/GFP nanoparticles plus systemic administration of GCV (NP-GFP + GCV, n = 8); intracranial infusion of HSVtk DNA plus systemic administration of GCV (DNA + GCV n = 8); or intracranial infusion of PBAE/HSVtk nanoparticles plus systemic administration of GCV (NP-HSVtk + GCV, n = 8). The median survival of the group receiving PBAE/HSVtk nanoparticles in combination with GCV is significantly longer compared to that of the untreated control group (p = 0.0012).